Literature DB >> 28503744

Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction.

Hiroaki Tanaka1, Michiko Kubo1, Masafumi Nii1, Sintarou Maki1, Takashi Umekawa1, Tomoaki Ikeda1.   

Abstract

For severe pre-eclampsia (PE) with fetal growth restriction (FGR), the only effective treatment is early delivery of the placenta. Clinicians are often forced to end the pregnancy because of maternal indications. We report a case of severe PE with FGR in which the PE was temporarily improved and pregnancy successfully prolonged with tadalafil, a phosphodiesterase 5 inhibitor. A 35-year-old primigravid woman presented at 27 3/7 weeks of gestation with severe PE and FGR. After commencing tadalafil administration, biochemical and angiogenic markers improved. Thereafter, hypertension and proteinuria temporarily improved. Importantly, the pregnancy was prolonged by 14 days after the initiation of tadalafil administration. Tadalafil may be a novel treatment for severe PE with FGR to prolong pregnancy.
© 2017 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  fetal growth restriction; pre-eclampsia; tadalafil

Mesh:

Substances:

Year:  2017        PMID: 28503744     DOI: 10.1111/jog.13335

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  5 in total

Review 1.  Phosphodiesterase Inhibition in the Treatment of Preeclampsia: What Is New?

Authors:  Anne Brandolt Larré; Fernando Sontag; Débora Montenegro Pasin; Nathália Paludo; Rayssa Ruszkowski do Amaral; Bartira Ercília Pinheiro da Costa; Carlos Eduardo Poli-de-Figueiredo
Journal:  Curr Hypertens Rep       Date:  2018-07-26       Impact factor: 5.369

2.  Tadalafil treatment in mice for preeclampsia with fetal growth restriction has neuro-benefic effects in offspring through modulating prenatal hypoxic conditions.

Authors:  Ryota Tachibana; Takashi Umekawa; Kento Yoshikawa; Takao Owa; Shoichi Magawa; Fumi Furuhashi; Makoto Tsuji; Shintaro Maki; Kyoko Shimada; Michiko K Kaneda; Masafumi Nii; Hiroaki Tanaka; Kayo Tanaka; Yuki Kamimoto; Eiji Kondo; Ineko Kato; Kenji Ikemura; Masahiro Okuda; Ning Ma; Takekazu Miyoshi; Hiroshi Hosoda; Masayuki Endoh; Tadashi Kimura; Tomoaki Ikeda
Journal:  Sci Rep       Date:  2019-01-18       Impact factor: 4.379

3.  Maternal Blood Concentration of Tadalafil and Uterine Blood Flow in Pregnancy.

Authors:  Hiroaki Tanaka; Shintaro Maki; Shoichi Magawa; Masafumi Nii; Kayo Tanaka; Kenji Ikemura; Kuniaki Toriyabe; Tomoaki Ikeda
Journal:  Medicina (Kaunas)       Date:  2019-10-21       Impact factor: 2.430

4.  Maternal tadalafil therapy for fetal growth restriction prevents non-alcoholic fatty liver disease and adipocyte hypertrophy in the offspring.

Authors:  Takuya Kawamura; Hiroaki Tanaka; Ryota Tachibana; Kento Yoshikawa; Shintaro Maki; Kuniaki Toriyabe; Hiroki Takeuchi; Shinji Katsuragi; Kayo Tanaka; Tomoaki Ikeda
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

5.  Tadalafil Treatment Ameliorates Hypoxia and Alters Placental Expression of Proteins Downstream of mTOR Signaling in Fetal Growth Restriction.

Authors:  Kyoka Tsuchiya; Kayo Tanaka; Hiroaki Tanaka; Shintaro Maki; Naosuke Enomoto; Sho Takakura; Masafumi Nii; Kuniaki Toriyabe; Shinji Katsuragi; Tomoaki Ikeda
Journal:  Medicina (Kaunas)       Date:  2020-12-21       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.